Intracoronary Use of GP IIb/IIIa Inhibitors in Percutaneous Coronary Interventions

By  

Current Vascular Pharmacology, Vol. 10, Iss. 4, 2012-07 ,pp. : 448-453

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES

By Luca Giuseppe   Sauro Rosario   Varricchio Attilio   Capasso Michele   Lanzillo Tonino   Manganelli Fiore   Mariello Ciro   Siano Francesco   Carbone Giannignazio   Pagliuca Maria   Rosato Giuseppe   Lorenzo Emilio  

Journal of Thrombosis and Thrombolysis, Vol. 30, Iss. 2, 2010-08 ,pp. : 133-141

Springer Publishing Company

Access to resources Recommend Favorite

Comparative Pharmacology of GP IIb/IIIa Antagonists

By Schrör Karsten   Weber Artur-Aron  

Journal of Thrombosis and Thrombolysis, Vol. 15, Iss. 2, 2003-04 ,pp. : 71-80

Springer Publishing Company

Access to resources Recommend Favorite

The Effect of Glycoprotein IIIa PIA1/A2 Polymorphism on the PFA-100 Response to GP IIbIIIa Receptor Inhibitors—The Importance of Anticoagulants Used

By Aalto-Setälä Katriina   Karhunen Pekka   Mikkelsson Jussi   Niemelä Kari  

Journal of Thrombosis and Thrombolysis, Vol. 20, Iss. 1, 2005-08 ,pp. : 57-63

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?

By  

Current Cardiology Reviews, Vol. 4, Iss. 2, 2008-05 ,pp. : 84-91

Bentham Science Publishers

Access to resources Recommend Favorite